What is eTheRNA?
Headquartered in Flanders, Belgium, and founded in 2013, eTheRNA is at the forefront of developing novel mRNA-based immunotherapies. The company's technology platform is designed to target a range of challenging diseases, including various forms of cancer and infectious diseases. By leveraging the power of messenger RNA, eTheRNA aims to create highly effective and targeted therapeutic interventions. The company's focus on this cutting-edge modality positions it as a key player in the evolving landscape of biopharmaceutical innovation.
How much funding has eTheRNA raised?
eTheRNA has raised a total of $103.7M across 2 funding rounds:
Series A
$26.7M
Series B
$77M
Series A (2016): $26.7M with participation from Omega Funds, Fund+ NV/SA, Life Sciences Partners, Boehringer Ingelheim, and PMV
Series B (2022): $77M led by PMV, Novalis LifeSciences, Life Sciences Partners, Omega Fund Management, Fund+ NV/SA, Professor Kenneth Chien, and Boehringer Ingelheim
Key Investors in eTheRNA
Omega Funds
Omega Funds is a venture capital firm focused on investing in exceptional founders and impactful products across therapeutic areas like oncology and immunology, aiming to bring science to patients.
Fund+ NV/SA
Fund+ NV/SA is an open-ended fund dedicated to long-term equity investments in innovative life sciences companies, primarily in Belgium, aiming to create sustainable shareholder value and societal impact.
Life Sciences Partners
Life Sciences Partners (LSP) is a European investment firm specializing in the life sciences sector, providing capital and strategic support to innovative companies.
What's next for eTheRNA?
With the recent substantial backing, eTheRNA is poised for accelerated growth and the advancement of its therapeutic pipeline. The strategic investment is expected to fuel further research and development, potentially enabling the company to move its lead candidates through clinical trials and towards commercialization. This financing round signifies a critical juncture for eTheRNA, providing the necessary resources to scale operations, expand its scientific team, and solidify its position in the competitive biotech sector. The company's trajectory suggests a strong emphasis on clinical validation and strategic partnerships to bring its innovative mRNA therapies to patients.
See full eTheRNA company page
